156 related articles for article (PubMed ID: 19423340)
1. Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin.
Pepe A; Sun L; Zanardi I; Wu X; Ferlini C; Fontana G; Bombardelli E; Ojima I
Bioorg Med Chem Lett; 2009 Jun; 19(12):3300-4. PubMed ID: 19423340
[TBL] [Abstract][Full Text] [Related]
2. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
Ferlini C; Raspaglio G; Mozzetti S; Cicchillitti L; Filippetti F; Gallo D; Fattorusso C; Campiani G; Scambia G
Cancer Res; 2005 Mar; 65(6):2397-405. PubMed ID: 15781655
[TBL] [Abstract][Full Text] [Related]
3. Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions.
Tang Y; Rodríguez-Salarichs J; Zhao Y; Cai P; Estévez-Gallego J; Balaguer-Pérez F; Redondo Horcajo M; Lucena-Agell D; Barasoain I; Díaz JF; Fang WS
Eur J Med Chem; 2017 Sep; 137():488-503. PubMed ID: 28624703
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of new-generation taxoids.
Ojima I; Chen J; Sun L; Borella CP; Wang T; Miller ML; Lin S; Geng X; Kuznetsova L; Qu C; Gallager D; Zhao X; Zanardi I; Xia S; Horwitz SB; Mallen-St Clair J; Guerriero JL; Bar-Sagi D; Veith JM; Pera P; Bernacki RJ
J Med Chem; 2008 Jun; 51(11):3203-21. PubMed ID: 18465846
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Cytotoxicity of 7,9-
Zhao Y; Wang TE; Mills A; Gago F; Fang WS
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181726
[TBL] [Abstract][Full Text] [Related]
6. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
7. Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
Yang CH; Wang C; Ojima I; Horwitz SB
J Nat Prod; 2018 Mar; 81(3):600-606. PubMed ID: 29517223
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
Battaglia A; Bernacki RJ; Bertucci C; Bombardelli E; Cimitan S; Ferlini C; Fontana G; Guerrini A; Riva A
J Med Chem; 2003 Nov; 46(23):4822-5. PubMed ID: 14584931
[TBL] [Abstract][Full Text] [Related]
9. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
Frapolli R; Marangon E; Zaffaroni M; Colombo T; Falcioni C; Bagnati R; Simone M; D'Incalci M; Manzotti C; Fontana G; Morazzoni P; Zucchetti M
Drug Metab Dispos; 2006 Dec; 34(12):2028-35. PubMed ID: 16963486
[TBL] [Abstract][Full Text] [Related]
11. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
Ojima I; Slater JC; Michaud E; Kuduk SD; Bounaud PY; Vrignaud P; Bissery MC; Veith JM; Pera P; Bernacki RJ
J Med Chem; 1996 Sep; 39(20):3889-96. PubMed ID: 8831755
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and SAR study of 3rd-generation taxoids bearing 3-CH
Wang C; Wang X; Sun Y; Taouil AK; Yan S; Botchkina GI; Ojima I
Bioorg Chem; 2020 Jan; 95():103523. PubMed ID: 31911305
[TBL] [Abstract][Full Text] [Related]
13. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and SAR study of Fluorine-containing 3rd-generation taxoids.
Wang C; Chen L; Sun Y; Guo W; Taouil AK; Ojima I
Bioorg Chem; 2022 Feb; 119():105578. PubMed ID: 34979464
[TBL] [Abstract][Full Text] [Related]
15. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57.
Cicchillitti L; Di Michele M; Urbani A; Ferlini C; Donat MB; Scambia G; Rotilio D
J Proteome Res; 2009 Apr; 8(4):1902-12. PubMed ID: 19714814
[TBL] [Abstract][Full Text] [Related]
16. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
[TBL] [Abstract][Full Text] [Related]
17. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes.
van Ark-Otte J; Samelis G; Rubio G; Lopez Saez JB; Pinedo HM; Giaccone G
Oncol Rep; 1998; 5(1):249-55. PubMed ID: 9458331
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
19. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
